DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis

Area of Science:

• Molecular Biology
• Genetics
• Oncology
• Neuroscience

Background:

• DYRK1A, a dual-specificity kinase, is encoded by a gene on human chromosome 21 within the Down syndrome critical region (DSCR).
• DYRK1A overexpression is linked to Down syndrome phenotypes, including intellectual disability, neurodegeneration, and heart defects.
• DYRK1A exhibits dual roles in tumorigenesis, acting as both a potential tumor suppressor and a pro-oncogenic factor.

Purpose of the Study:

• To review the multifaceted role of DYRK1A in tumorigenesis.
• To elucidate DYRK1A's involvement in key cancer hallmark pathways.
• To discuss targeting DYRK1A for cancer and neurodegenerative disorder management.

Main Methods:

• Literature review focusing on DYRK1A's function in cancer.
• Analysis of DYRK1A's participation in proliferative signaling, transcription, stress response, DNA damage repair, apoptosis, and angiogenesis.
• Synthesis of current research on DYRK1A's dual role in cancer development and progression.

Main Results:

• DYRK1A is implicated in various cancer hallmarks, suggesting complex regulatory functions.
• Evidence supports both tumor-suppressive and oncogenic activities of DYRK1A depending on the cellular context.
• DYRK1A's dual activity highlights its potential as a therapeutic target.

Conclusions:

• DYRK1A plays a significant, context-dependent role in tumorigenesis.
• Understanding DYRK1A's complex functions is crucial for developing targeted therapies.
• Targeting DYRK1A presents a promising strategy for managing both cancer and neurodegenerative diseases.